Faron Pharmaceuticals
2.06 EUR
+1.98 %
5,521 following
FARON
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
Valuation
Income statement
Quarterly estimates
Valuation
Dividend yield
Median 2020-2024
P/B
Median 2020-2024
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 3.30 | 2.91 | 3.24 | 3.71 | 3.77 | 2.24 | 2.06 | 2.06 | 2.06 | 2.06 | |
| Shares | 31.0 | 43.3 | 46.9 | 53.2 | 59.8 | 68.8 | 104.6 | 116.6 | 120.6 | 124.5 | 127.8 |
| Market cap | 142.9 | 136.5 | 172.5 | 221.6 | 259.3 | 234.4 | 240.2 | 248.4 | 256.5 | 263.3 | |
| Enterprise value | 138.2 | 135.1 | 169.0 | 227.5 | 265.3 | 236.7 | 243.0 | 274.9 | 307.8 | 333.9 | |
| EV/S | - | 34,556.0 | 33,775.4 | 42,241.4 | 56,880.5 | 66,337.2 | 59,166.2 | 60,749.4 | 68,716.0 | 76,955.1 | 33,387.4 |
| EV/EBITDA | - | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT (adj.) | - | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| EV/EBIT | - | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E (adj.) | - | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/E | - | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | - | 88.7 | neg. | 58.8 | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/S | - | 35,714.3 | 34,117.3 | 43,117.9 | 55,389.8 | 64,831.5 | 58,589.4 | 60,049.0 | 62,091.5 | 64,134.0 | 26,330.5 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | |
| Equity ratio | 4.6 % | 15.8 % | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -78.0 % | -53.0 % | -455.4 % | -889.8 % | -2,077.7 % |
| Gearing ratio | -524.4 % | -287.8 % | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -23.6 % | -33.0 % | -81.8 % | -89.4 % | -89.0 % |